Amgen invests heavily in innovative medicines, transformative research and world-class bio-manufacturing. Amgen is present in approximately 100 countries reaching millions of people in the fight against serious illnesses.

In 2019, Amgen acquired the Copenhagen-based biopharmaceutical company Nuevolution, now known as Amgen Research Copenhagen. The acquisition of Nuevolution and its DNA-encoded library platform radically expanded Amgen’s small molecule screening capability.

Denmark is one of Amgen’s preferred locations for running clinical trials. This brings important experimental therapies to Danish patients with no other treatment options available, while also contributing valuable knowledge to the research community in Denmark.

"Denmark has a strong position in Amgen when it comes to competing with other countries on where the clinical trials should be placed. This is based on the fact that Denmark has a long tradition for clinical research and a lot of interest and experience in this field. Consequently, sites in Denmark typically deliver trial data of high quality and within agreed timelines. Despite our small size, Amgen Denmark is in the top league and that is definitely something to be proud of."

Birgitte Claudius

Medical Director, Amgen Denmark

Denmark has the second highest number of clinical trials per capita in Europe and also ranks the best country in Europe for biotech research and development in 2019 (Nordic Life Science News).

"The fact that Amgen has chosen Denmark as one of its preferred locations for clinical trials will undoubtedly strengthen the clinical research in Denmark for the benefit of patients, the healthcare system and companies. Invest in Denmark is confident that the partnership between Amgen and Trial Nation will contribute to a ensuring that Denmark remains one of the leading European countries in clinical research."

Maria Nilaus Tarp

Director, Invest in Denmark 

Invest in Denmark has been in dialogue with Amgen since 2013, with a main focus on trying to attract clinical research and other R&D activities to Denmark. Amgen’s core activities highly correlate with the strong competencies available in Denmark within oncology, cardiovascular and neuroscience. The provided services have included introducing Amgen to the Danish life science cluster and opportunities in Denmark, understanding the framework conditions and establishment process and facilitating meetings with relevant partner organizations in relation to setting up clinical trials. 

"We need strong and innovative Public-Private Partnerships to make Denmark an even more attractive place to run clinical research. Therefore, we are very happy to work with our peers in Trial Nation with the common goal of strengthening the clinical trial activities in Denmark. It’s very successful. Denmark has a lot of opportunities to build on and it is fantastic to see how far we get by working together. I see a great future with huge foreign investments in Danish clinical research, because we are continuously developing our research environment and business framework."

Birgitte Claudius

Medical Director, Amgen Denmark